To characterize the antibody response after CoronaVac vaccination, which has a distinct antigenic composition compared to other vaccines and natural infection, we measured plasma RBD-ACE2 blocking antibody levels against various SARS-CoV-2 strains using multiplex sVNT30,31, anti-spike antibody levels using ECLIA37, and anti-RBD IgG antibody levels using in-house ELISA20 in vaccinated individuals on days 0 (pre-vaccination), 14, and 28 after the second dose (Fig. 2, Supplementary Tables S1–S3). The gene discussed is ACE2; the disease is infection.